ADCs targeting nectin‐4 were approved to treat bladder cancer in 2019 by the FDA58 and an ADC targeting HER‐2 was approved in 2021 by the CSCO Guideline depending on the C005 research study59 . Here, ERBB2 is linked to urinary bladder carcinoma.